Insider Buying: Bluejay Diagnostics (NASDAQ:BJDX) CEO Buys $25,000.00 in Stock

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) CEO Indranil Dey purchased 12,500 shares of Bluejay Diagnostics stock in a transaction that occurred on Saturday, March 14th. The shares were acquired at an average price of $2.00 per share, with a total value of $25,000.00. Following the acquisition, the chief executive officer directly owned 12,501 shares of the company’s stock, valued at $25,002. This trade represents a 1,250,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Bluejay Diagnostics Stock Performance

Bluejay Diagnostics stock opened at $1.78 on Thursday. Bluejay Diagnostics, Inc. has a 52 week low of $1.62 and a 52 week high of $16.68. The stock has a market capitalization of $1.83 million, a P/E ratio of -0.15 and a beta of 0.72. The stock has a 50-day simple moving average of $1.89 and a 200 day simple moving average of $3.09.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($1.95) EPS for the quarter.

Institutional Investors Weigh In On Bluejay Diagnostics

A hedge fund recently bought a new stake in Bluejay Diagnostics stock. Armistice Capital LLC acquired a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned 9.15% of Bluejay Diagnostics as of its most recent SEC filing. 18.47% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has an average rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.